Acute myeloid leukemia during pregnancy: a single institutional experience with 17 patients and literature review

International Journal of Hematology
Yi-Wei LiCan Chen

Abstract

Management of acute myeloid leukemia during pregnancy (P-AML) is a challenging endeavor with limited evidence-based information available. To truly achieve the goal of improving P-AML patients, additional evidence-based research is necessary. We retrospectively reviewed cases of 17 patients diagnosed with P-AML, including seven for acute promyelocytic leukemia (APL) from January 2012 to June 2019. Among the non-APL, 90% patients (9/10) ended pregnancy prior to induction chemotherapy. The median intervals between diagnosis and start of chemotherapy were 5 days (range 1-14 days). Four patients elected to delay chemotherapy by more than one week. Of the seven APL patients, six received all-trans retinoic acid (ATRA) before the diagnostic molecular results. Five patients underwent cesarean sections (CS) and all newborns were alive (four preterm and one full-term deliveries). Overall, approximately 94% of the patients (16/17) are currently alive in remission. To treat P-AML patients in a safer manner, balancing the risk of progressing to advanced disease and proceeding with pregnancy is required. We consider a slight delay (less than 14 days) in the termination of pregnancy may not differ the prognosis to patients with non-APL. For ...Continue Reading

References

Oct 3, 1985·The New England Journal of Medicine·E J LammerI T Lott
Jul 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E E ReynosoM A Baker
Jun 30, 1998·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·M S GolubN Baumrind
May 30, 2001·Leukemia & Lymphoma·L J GreenlundA Tefferi
Jul 30, 2002·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·B L SiuA L Fenrich
Oct 16, 2004·Expert Review of Anticancer Therapy·Boaz WeiszMichael Lishner
Oct 7, 2005·Pharmacotherapy·Dawn M NiedermeierPhilip D Hall
Nov 21, 2007·Thrombosis Research·Frederick R RicklesTiziano Barbui
Dec 1, 2010·Clinical Lymphoma, Myeloma & Leukemia·Martin TallmanMiguel A Sanz
May 12, 2011·European Journal of Haematology·Gunnar LarforsSven Cnattingius
Feb 13, 2013·Lancet·Felicetto Ferrara, Charles A Schiffer
Nov 26, 2013·Blood·Dragana Milojkovic, Jane F Apperley
Apr 10, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J G C van HasseltF Amant
May 23, 2014·International Journal of Laboratory Hematology·Y NakajimaS Fujisawa
Jun 25, 2014·British Journal of Haematology·Massimo BrecciaFrancesco Lo Coco
Jul 24, 2014·Future Oncology·Irit Avivi, Benjamin Brenner
Jun 18, 2015·British Journal of Haematology·Sahra AliUNKNOWN British Committee for Standards in Haematology
Jun 25, 2015·British Journal of Haematology·Andrew K McGregor, Emma Das-Gupta
Jun 26, 2015·Leukemia & Lymphoma·Vivek VermaVijaya Raj Bhatt
Jun 11, 2016·Critical Reviews in Oncology/hematology·Semra Paydas
Aug 27, 2016·Leukemia & Lymphoma·Nosha FarhadfarNaseema Gangat
Jul 14, 2017·Leukemia & Lymphoma·Netanel A HorowitzIrit Avivi
May 24, 2019·Circulation Research·Joshua A CowgillDouglas B Sawyer
Jan 1, 2018·Cancer Treatment and Research Communications·Mohamed MabedMona Talaab
Sep 5, 2019·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Sabrina NolanHaim Arie Abenhaim
Oct 24, 2019·American Journal of Clinical Oncology·Maria La NasaElyce Cardonick

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.